切换至 "中华医学电子期刊资源库"

中华移植杂志(电子版) ›› 2021, Vol. 15 ›› Issue (01) : 60 -63. doi: 10.3877/cma.j.issn.1674-3903.2021.01.014

所属专题: 文献

综述

肝移植术后并发非酒精性脂肪性肝病研究进展
党智萍1, 马莉娜2, 饶伟3, 孔心涓1,()   
  1. 1. 266000 青岛大学附属医院消化内科
    2. 266000 青岛大学附属医院健康管理中心
    3. 266000 青岛大学附属医院器官移植中心 肝脏病中心 移植医学研究所
  • 收稿日期:2020-09-20 出版日期:2021-02-25
  • 通信作者: 孔心涓

Research progress of non-alcoholic fatty liver disease after liver transplantation

Zhiping Dang1, Lina Ma2, Wei Rao3, Xinjuan Kong1,()   

  1. 1. Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao 266000, China
    2. Health Management Center, the Affiliated Hospital of Qingdao University, Qingdao 266000, China
    3. Organ Transplantation Center, Division of Hepatology Disease Center, Institute of Transplantation Science, the Affiliated Hospital of Qingdao University, Qingdao 266000, China
  • Received:2020-09-20 Published:2021-02-25
  • Corresponding author: Xinjuan Kong
引用本文:

党智萍, 马莉娜, 饶伟, 孔心涓. 肝移植术后并发非酒精性脂肪性肝病研究进展[J/OL]. 中华移植杂志(电子版), 2021, 15(01): 60-63.

Zhiping Dang, Lina Ma, Wei Rao, Xinjuan Kong. Research progress of non-alcoholic fatty liver disease after liver transplantation[J/OL]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(01): 60-63.

肝移植是各种终末期肝病的有效治疗方法,供肝需求量日益增加。非酒精性脂肪性肝病(NAFLD)已成为越来越受关注的慢性肝病问题,近来国际专家共识对其提出了新的命名——代谢相关脂肪性肝病。随着肝移植数量的不断增加,受者术后发生NAFLD的问题也逐渐引起重视。现就肝移植后NAFLD的发生、危险因素及预防治疗措施等做一综述。

Liver transplantation is an effective treatment for patients with various end-stage liver diseases, and the demand of graft livers is increasing. Non-alcoholic fatty liver disease (NAFLD) is getting more and more attention as a chronic liver disease. Recently, the international expert consensus has proposed a new name for NAFLD-metabolic associated fatty liver disease. With the increasing number of liver transplantation, the problems of NAFLD after transplantation have attracted more and more attention. This paper reviews the occurrence, risk factors, measures of prevention and treatment in NAFLD after liver transplantation.

1
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Clin Liver Dis (Hoboken), 2018, 20, 11(4):81.
2
Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1991.
3
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease - Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1):73-84.
4
Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398.
5
Wu Y, Zheng Q, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis[J]. Hepatol Int, 2020,14(2):259-269.
6
Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary[J]. J Gastroenterol Hepatol, 2007, 22(6): 775-777.
7
Kwon CHD, Joh JW, Lee KW, et al. Safety of donors with fatty liver in liver transplantation[J]. Transplant Proc, 2006, 38(7): 2106-2107.
8
Nikeghbalian S, Nejatollahi SMR, Salahi H, et al. Does donor′s fatty liver change impact on early mortality and outcome of liver transplantation[J]. Transplant Proc, 2007, 39(4): 1181-1183.
9
Trotter JF. Thin chance for fat people (to become living donors)[J]. Liver Transpl, 2001, 7(5): 415-417.
10
Brandhagen D, Fidler J, Rosen C. Evaluation of the donor liver for living donor liver transplantation[J]. Liver Transpl, 2003, 9(10 Suppl 2): S16-S28.
11
Kim H, Lee K, Lee KW, et al. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation[J]. Clin Transplant, 2014, 28(5): 521-529.
12
Kim H, Lee KW, Lee K, et al. Effect of PNPLA3 I148M polymorphism on histologically proven non-alcoholic fatty liver disease in liver transplant recipients[J]. Hepatol Res, 2018, 48(3): E162-E171.
13
Narayanan P, Mara K, Izzy M, et al. Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation[J]. Transplantation, 2019, 103(1): e14-e21.
14
Vallin M, Guillaud O, Boillot O, et al. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: Natural history based on liver biopsy analysis[J]. Liver Transpl, 2014, 20(9):1064-1071.
15
Germani G, Laryea M, Rubbia-Brandt L, et al. Management of recurrent and de novo NAFLD/NASH after liver transplantation[J]. Transplantation, 2019, 103(1): 57-67.
16
Narayanan P, Mara K, Dierkhising R, et al. 425 underlying NASH and recurrent or de novo allograft steatosis are predictive of long term cardiovascular events in liver transplant recipients[J]. Gastroenterology, 2016, 150(4): S1033.
17
Hanouneh IA, Macaron C, Lopez R, et al. Recurrence of disease following liver transplantation: nonalcoholic steatohepatitis vs hepatitis C virus infection[J]. Int J Organ Transplant Med, 2011, 2(2): 57-65.
18
Alten TA, Negm AA, Voigtländer T, et al. Safety and performance of liver biopsies in liver transplant recipients[J]. Clin Transplant, 2014, 28(5): 585-589.
19
van Werven JR, Marsman HA, Nederveen AJ, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy[J]. Radiology, 2010, 256(1): 159-168.
20
Hepburn MJ, Vos JA, Fillman EP, et al. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study[J]. BMC gastroenterology, 2005, 5: 14.
21
Bhat M, Tazari M, Sebastiani G. Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis[J]. PLoS One, 2017, 12(9): e0185192.
22
Pfitzmann R, Nüssler NC, Hippler-Benscheidt M, et al. Long-term results after liver transplantation[J]. Transpl Int, 2008, 21(3): 234-246.
23
Laryea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events[J]. Liver Transpl, 2007, 13(8): 1109-1114.
24
Bianchi G, Marchesini G, Marzocchi R, et al. Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression[J]. Liver Transpl, 2008, 14(11):1648-1654.
25
Miller LW. Cardiovascular toxicities of immunosuppressive agents[J]. Am J Transplant, 2002, 2(9): 807-818.
26
Charlton M, Rinella M, Patel D, et al. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: Results of a randomized multicenter study[J]. Transplantation, 2017, 101(12): 2873-2882.
27
Dumortier J, Giostra E, Belbouab S, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of " seed and soil" [J]. Am J Gastroenterol, 2010, 105(3): 613-620.
28
Hübscher SG. What is the long-term outcome of the liver allograft?[J]. J Hepatol, 2011, 55(3): 702-717.
29
Finkenstedt A, Auer C, Glodny B, et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis[J]. Clin Gastroenterol Hepatol, 2013, 11(12): 1667-1672.
30
Miyaaki H, Miuma S, Taura N, et al. PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C[J]. Hepatol Res, 2018, 48(3): E335-E339.
31
Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2014, 46(4): 352-356.
32
Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis[J]. Hepatology, 2015, 62(6): 1742-1756.
33
Textor SC, Taler SJ, Canzanello VJ, et al. Posttransplantation hypertension related to calcineurin inhibitors[J]. Liver Transpl, 2000, 6(5):521-530.
34
Mohameda O, Jamesp W. FDA adverse event reports on statin-associated rhabdomyolysis[J]. Ann Pharmacother, 2002, 36(2): 288-295.
[1] 郝玥萦, 毛盈譞, 张羽, 汪佳旭, 韩林霖, 匡雯雯, 孟瑶, 杨秀华. 超声引导衰减参数成像评估肝脂肪变性及其对心血管疾病风险的预测价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 770-777.
[2] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[3] 曹琮沅, 黄烁金, 何倩婷, 王安训. 平阳霉素复合剂治疗口腔颌面部脉管畸形的有效性和安全性[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 368-374.
[4] 严华悦, 刘子祥, 周少波. 磷酸烯醇式丙酮酸羧激酶-1在恶性肿瘤中的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 452-456.
[5] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[6] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[7] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[8] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[9] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[10] 傅斌生, 冯啸, 杨卿, 曾凯宁, 姚嘉, 唐晖, 刘剑戎, 魏绪霞, 易慧敏, 易述红, 陈规划, 杨扬. 脂肪变性供肝在成人劈离式肝移植中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 789-794.
[11] 中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-肛管癌(2024 版)[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 441-449.
[12] 吴天宇, 刘子璇, 杨浦鑫, 贾思明, 丁凯, 程晓东, 李泳龙, 陈伟, 吕红芝, 张奇. 腰椎间盘突出症保守治疗进展[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 379-384.
[13] 颜世锐, 熊辉. 感染性心内膜炎合并急性肾损伤患者的危险因素探索及死亡风险预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 618-624.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?